-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Assumes BridgeBio Oncology at Outperform, Announces Price Target of $22

Benzinga·06/22/2026 17:34:27
Listen to the news
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $22.